Clinical trial NCT01898923: Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
Official title: Randomized Controlled Study to Evaluate the Efficacy and Safety of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetic Foot
Keywords: WH-1,Diabetic Foot,Ulcer
Lead sponsor: Oneness Biotech Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2013-07-15
Enrollment: 236
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the efficacy of the new treatment of WH-1 ointment compared to Aquacel® Hydrofiber® dressing, applied to chronic diabetic foot ulcers for up to 16 weeks.An additional objective of this study is to collect safety information including adverse events and clinical laboratory abnormalities.

Detailed description: This trial is designed as a randomized, evaluator blinded, active-controlled, multi-center study comparing the efficacy and safety of WH-1 ointment and Aquacel® Hydrofiber® dressing in the treatment of diabetic foot ulcers. Independent evaluators who blinded to subjects' treatment will evaluate whether the wound has healed. Eligible subjects will be randomized to receive either WH-1 ointment or Aquacel® Hydrofiber® dressing in a 1:1 allocation. The study treatment will be applied to the selected ulcer for a maximum period of 16 weeks, until the wound/ulcer closure (wound size of 0) for two consecutive visits at least 2 weeks apart, or until the subject exited the study as treatment failure. After that, all subjects regardless of wound healing at the end of comparison period will be followed for 12 weeks to investigate durability. During the follow-up period, Aquacel® Hydrofiber® dressing will be applied for subjects who have unhealed or with recurrent wound. Each target ulcer with wound photographs for blind assessment will be monitored at each scheduled visit.

One interim analysis is planned at around 50% of study information; the final analysis will be conducted at the end of the study.

Eligibility criteria: Inclusion Criteria

1. Has signed a written informed consent prior to the first study evaluation;
2. Male or female is at least 20 and \< 80 years of age;
3. Diabetes mellitus (type 1 or 2) with an HbA1c \< 12.0% measured during screening or within three months prior to randomization;
4. An ankle brachial index on the target limb at least 0.8 measured during screening or within three months prior to randomization;
5. The target ulcer must have the following characteristics:

   * Grade 1 or 2 per Wagner Ulcer Classification System;
   * No higher than the ankle;
   * No active infected;
   * A cross-sectional area of between 1 and 25 cm2 post-debridement;
   * Present for at least 4 weeks before randomization;
6. If female and of childbearing potential has a negative pregnancy test and is not breastfeeding at screening visit;
7. Able and willing to attend the scheduled visits and comply with study procedures.

Exclusion Criteria:

1. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement;
2. Acute Charcot's neuroarthropathy as determined by clinical and/or radiographic examination;
3. Has undergone revascularization procedure aimed at increasing blood flow in the treatment target limb \< 4 weeks prior to randomization;
4. Poor nutritional status defined as an albumin \< 2.5 g/dL;
5. Aspartate Aminotransferase(AST, GOT) and/or Alanine Aminotransferase(ALT, GPT) \>3 x the normal upper limit;
6. Serum Creatinine \>2 x the normal upper limit;
7. Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or systemic corticosteroids less than 4 weeks before randomization;
8. Use of any investigational drug or therapy within the 4 weeks prior to randomization;
9. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse problem, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance;
10. Judged by the investigator not to be suitable for the study for any other reason.

Primary outcomes:
measure: Number of Participants With Complete Ulcer Closure
timeFrame: 16 weeks
Secondary outcomes:
measure: The Time of Healing Rate
timeFrame: 16 weeks
measure: Change in Ulcer Area
timeFrame: 16 weeks
measure: Percentage of Participants With a 50% Reduction of Ulcer Surface Area
timeFrame: 16 weeks
measure: Incidence of Infection of the Target Ulcer
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Fresno
country: United States
facility: Limb Preservation Platform, Inc.
state: California
city: Guangzhou
country: China
facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University
state: Guangdong
city: Guanzhou
country: China
facility: Nanfang Hospital of Southern Medical University
state: Guangdong
city: Guanzhou
country: China
facility: The First Affiliated Hospital, Sun Yat-sen University
state: Guangdong
city: Luoyang
country: China
facility: The First Affiliated Hospital of Henan Science & Technology University
state: Henan
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
city: Zhenjiang
country: China
facility: Affiliated Hospital of Jiangsu University
state: Jiangsu
city: Jinan
country: China
facility: Shandong Provincial Hospital
state: Shandong
city: Shanghai
country: China
facility: Ruijin Hospital, Shanghai Jiaotong University School of Medicine
state: Shanghai
city: Shanghai
country: China
facility: Shanghai TCM-Interated Hospital
state: Shanghai
city: Kaohsiung
country: Taiwan
facility: Chang Gung Medical Hospital_Kaohsiung
city: New Taipei City
country: Taiwan
facility: Buddhist Tzu Chi Medical Hospital
city: New Taipei City
country: Taiwan
facility: MacKay Memorial Hospital-Tamsui Branch
city: Taichung City
country: Taiwan
facility: China Medical University Hospital
city: Tainan City
country: Taiwan
facility: Chi Mei Medical Center-Yongkang
city: Taipei City
country: Taiwan
facility: MacKay Memorial Hospital-Taipei Branch
city: Taipei City
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei City
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taipei City
country: Taiwan
facility: Tri-Service General Hospital
city: Taoyuan City
country: Taiwan
facility: Chang Gung Medical Hospital_Linkou
city: Yunlin
country: Taiwan
facility: China Medical University Hospital-Beigang Branch
Study officials:
affiliation: Oneness Biotech
name: Henry Chang
role: STUDY_DIRECTOR
References:
citation: Huang YY, Lin CW, Cheng NC, Cazzell SM, Chen HH, Huang KF, Tung KY, Huang HL, Lin PY, Perng CK, Shi B, Liu C, Ma Y, Cao Y, Li Y, Xue Y, Yan L, Li Q, Ning G, Chang SC. Effect of a Novel Macrophage-Regulating Drug on Wound Healing in Patients With Diabetic Foot Ulcers: A Randomized Clinical Trial. JAMA Netw Open. 2021 Sep 1;4(9):e2122607. doi: 10.1001/jamanetworkopen.2021.22607.